Atinvicitinib is a selective second-generation Janus kinase (JAK) inhibitor developed as a veterinary medication to treat pruritus and clinical signs associated with allergic and atopic dermatitis in dogs.… Read more
Atinvicitinib is a selective second-generation Janus kinase (JAK) inhibitor developed as a veterinary medication to treat pruritus and clinical signs associated with allergic and atopic dermatitis in dogs. This category provides essential pharmaceutical reference standards, including the active pharmaceutical ingredient, potential process-related impurities, and stereoisomers like ent-Atinvicitinib, trans-Atinvicitinib, and cis-Atinvicitinib. Analytical laboratories utilize these high-quality compounds for comprehensive impurity profiling, method validation, and rigorous quality control testing of veterinary drug formulations. Additionally, stable isotope-labelled compounds, such as Atinvicitinib-13C-d3, serve as critical internal standards for accurate quantification in mass spectrometry-based bioanalytical assays. By offering this range of related compounds, the catalogue supports precise analytical investigations and regulatory compliance, ensuring the safety and efficacy of the medicinal product throughout its development and manufacturing lifecycle.